Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02104700 | Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir | PHASE2 | COMPLETED | 150 | — | — | Apr 1, 2014 | Jul 1, 2016 | Mar 17, 2021 | 1 | Rwanda |
To compare proportion of subjects successfully maintaining a plasma viral load \<200 copies /mL at week 24 in subjects randomized to rilpivirine/emtricitabine/tenofovir vs. in those randomized to initially continue nevirapine-based ART in this pilot study.
| Arm | Type | Description |
|---|---|---|
| Rilpivirine/Emtricitabine/Tenofovir | ACTIVE_COMPARATOR | "Immediate switch": RILPIVIRINE/ EMTRICITABINE /TENOFOVIR FDC QDAY at randomization. |
| Nevirapine/Lamivudine/ plus other NNRTI | ACTIVE_COMPARATOR | "Delayed switch": Continue NEVIRAPINE 200MG BID + LAMIVUDINE 300MG + OTHER NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI) through 24 weeks then switch to RILPIVIRINE 25MG/ EMTRICITABINE 200MG/TENOFOVIR 300MG FDC QDAY and then follow through 48 weeks. |
| Name | Type | Description |
|---|---|---|
| Rilpivirine/Emtricitabine/Tenofovir | DRUG | Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday |
Inclusion Criteria: * HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry. A second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test or a previous detectable HIV RNA level * HIV RNA ...